ABSTRACT
Previous studies indicate that superoxide is important in the modulation of blood pressure but have not specifically identified the cell types or organs involved. We created mice with loxP sites flanking the extracellular superoxide dismutase (SOD3) gene. These mice were crossed with mice expressing inducible Cre-recombinase driven by the smooth muscle myosin heavy chain promoter allowing tissue-specific deletion of SOD3. Deletion of SOD3 increased vascular superoxide and reduced vascular NO levels as detected by electron spin resonance. Despite these changes in NO and superoxide, we did not observe increases in vascular inflammation caused by angiotensin II. Moreover, deletion of vascular SOD3 did not augment hypertension in response to angiotensin II. In additional studies, we also deleted SOD3 from the circumventricular organs by intracerebroventricular injection of an adenovirus encoding Cre-recombinase. Although this raised blood pressure and augmented the hypertension caused by angiotensin II, these responses were not further increased by vascular deletion of SOD3. These data suggest that the extracellular superoxide dismutase in vascular smooth muscle is not involved in the genesis of angiotensin II-induced hypertension and further emphasize the role of central SOD3 in the modulation of blood pressure.
Subject(s)
Aorta/metabolism , Blood Pressure/physiology , Hypertension/metabolism , Muscle, Smooth, Vascular/metabolism , Superoxide Dismutase/metabolism , Angiotensin II/pharmacology , Animals , Aorta/physiopathology , Blood Pressure/drug effects , Hydrogen Peroxide/metabolism , Hypertension/chemically induced , Hypertension/genetics , Hypertension/physiopathology , Mice , Mice, Transgenic , Muscle, Smooth, Vascular/physiopathology , Nitric Oxide/metabolism , Superoxide Dismutase/geneticsABSTRACT
OBJECTIVE: Interleukin 17A (IL17A) is involved in many inflammatory processes, but its role in atherosclerosis remains controversial. We examined the role of IL17A in mouse and human atherosclerosis. METHODS AND RESULTS: Atherosclerosis was induced in apolipoprotein E (ApoE)(-/-) and IL17A/ApoE(-/-) mice using high-fat feeding, angiotensin II infusion, or partial carotid ligation. In ApoE(-/-) mice, 3 months of high-fat diet induced interferon-γ production by splenic lymphocytes, and this was abrogated in IL17A/ApoE(-/-) mice. IL17A/ApoE(-/-) mice had reduced aortic superoxide production, increased aortic nitric oxide levels, decreased aortic leukocyte and dendritic cell infiltration, and reduced weight gain after a high-fat diet compared with ApoE(-/-) mice. Despite these favorable effects, IL17A deficiency did not affect aortic plaque burden after a high-fat diet or angiotensin II infusion. In a partial carotid ligation model, IL17A deficiency did not affect percentage of stenosis but reduced outward remodeling. In this model, neutralization of the related isoform, IL17F, in IL17A/ApoE(-/-) mice did not alter atherosclerosis. Finally, there was no correlation between IL17A levels and carotid intima-media thickness in humans. CONCLUSIONS: IL17 contributes to vascular and systemic inflammation in experimental atherosclerosis but does not alter plaque burden. The changes in plaque composition caused by IL17 might modulate plaque stability.
Subject(s)
Aortic Diseases/immunology , Apolipoproteins E/deficiency , Atherosclerosis/immunology , Carotid Artery Diseases/immunology , Inflammation/immunology , Interleukin-17/blood , Interleukin-17/metabolism , Aged , Angiotensin II , Animals , Antibodies, Neutralizing/administration & dosage , Aorta/immunology , Aorta/metabolism , Aortic Diseases/genetics , Aortic Diseases/metabolism , Aortic Diseases/pathology , Apolipoproteins E/genetics , Atherosclerosis/genetics , Atherosclerosis/metabolism , Atherosclerosis/pathology , Carotid Arteries/surgery , Carotid Artery Diseases/genetics , Carotid Artery Diseases/metabolism , Carotid Artery Diseases/pathology , Cells, Cultured , Dendritic Cells/immunology , Dietary Fats , Disease Models, Animal , Female , Humans , Inflammation/genetics , Inflammation/metabolism , Inflammation/pathology , Interferon-gamma/metabolism , Interleukin-17/deficiency , Interleukin-17/genetics , Interleukin-17/immunology , Ligation , Lymphocytes/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Nitric Oxide/metabolism , Spleen/immunology , Superoxides/metabolism , Time FactorsABSTRACT
BACKGROUND: The pathogenesis of hypertension remains poorly understood, and treatment is often unsuccessful. Recent evidence suggests that the adaptive immune response plays an important role in this disease. Various hypertensive stimuli cause T-cell activation and infiltration into target organs such as the vessel and the kidney, which promotes vascular dysfunction and blood pressure elevation. Classically, T-cell activation requires T-cell receptor ligation and costimulation. The latter often involves interaction between B7 ligands (CD80 and CD86) on antigen-presenting cells with the T-cell coreceptor CD28. This study was therefore performed to examine the role of this pathway in hypertension. METHODS AND RESULTS: Angiotensin II-induced hypertension increased the presence of activated (CD86(+)) dendritic cells in secondary lymphatic tissues. Blockade of B7-dependent costimulation with CTLA4-Ig reduced both angiotensin II- and deoxycorticosterone acetate (DOCA)-salt-induced hypertension. Activation of circulating T cells, T-cell cytokine production, and vascular T-cell accumulation caused by these hypertensive stimuli were abrogated by CTLA4-Ig. Furthermore, in mice lacking B7 ligands, angiotensin II caused minimal blood pressure elevation and vascular inflammation, and these effects were restored by transplantation with wild-type bone marrow. CONCLUSIONS: T-cell costimulation via B7 ligands is essential for development of experimental hypertension, and inhibition of this process could have therapeutic benefit in the treatment of this disease.
Subject(s)
B7-1 Antigen/genetics , CD28 Antigens/genetics , Gene Deletion , Hypertension/immunology , Hypertension/prevention & control , Lymphocyte Activation/genetics , T-Lymphocytes/immunology , Abatacept , Angiotensin II/administration & dosage , Angiotensin II/physiology , Animals , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/therapeutic use , B7-1 Antigen/metabolism , B7-1 Antigen/physiology , B7-2 Antigen/biosynthesis , B7-2 Antigen/metabolism , B7-2 Antigen/physiology , CD28 Antigens/physiology , Cells, Cultured , Hypertension/pathology , Immunoconjugates/administration & dosage , Immunoconjugates/therapeutic use , Immunosuppressive Agents/administration & dosage , Ligands , Lymphocyte Activation/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout , Random Allocation , T-Lymphocytes/metabolism , T-Lymphocytes/pathologyABSTRACT
We have shown previously that T cells are required for the full development of angiotensin II-induced hypertension. However, the specific subsets of T cells that are important in this process are unknown. T helper 17 cells represent a novel subset that produces the proinflammatory cytokine interleukin 17 (IL-17). We found that angiotensin II infusion increased IL-17 production from T cells and IL-17 protein in the aortic media. To determine the effect of IL-17 on blood pressure and vascular function, we studied IL-17(-/-) mice. The initial hypertensive response to angiotensin II infusion was similar in IL-17(-/-) and C57BL/6J mice. However, hypertension was not sustained in IL-17(-/-) mice, reaching levels 30-mm Hg lower than in wild-type mice by 4 weeks of angiotensin II infusion. Vessels from IL-17(-/-) mice displayed preserved vascular function, decreased superoxide production, and reduced T-cell infiltration in response to angiotensin II. Gene array analysis of cultured human aortic smooth muscle cells revealed that IL-17, in conjunction with tumor necrosis factor-alpha, modulated expression of >30 genes, including a number of inflammatory cytokines/chemokines. Examination of IL-17 in diabetic humans showed that serum levels of this cytokine were significantly increased in those with hypertension compared with normotensive subjects. We conclude that IL-17 is critical for the maintenance of angiotensin II-induced hypertension and vascular dysfunction and might be a therapeutic target for this widespread disease.
Subject(s)
Angiotensin II/pharmacology , Atherosclerosis/blood , Diabetes Mellitus, Type 2/blood , Hypertension/blood , Interleukin-17/blood , Vascular Diseases/metabolism , Animals , Atherosclerosis/physiopathology , Cells, Cultured , Cohort Studies , Diabetes Mellitus, Type 2/physiopathology , Disease Models, Animal , Female , Humans , Hypertension/physiopathology , Lymphocyte Activation/drug effects , Male , Mice , Mice, Inbred C57BL , Probability , Random Allocation , Reference Values , T-Lymphocytes/metabolism , Vascular Diseases/chemically inducedABSTRACT
Recent success using a steroid-free immunosuppressive regimen has renewed enthusiasm for the use of islet transplantation to treat diabetes. Toxicities associated with the continued use of a calcineurin inhibitor may limit the wide-spread application of this therapy. Biological agents that block key T-cell costimulatory signals, in particular the CD28 pathway, have demonstrated extraordinary promise in animal models. LEA29Y (BMS-224818), a mutant CTLA4-Ig molecule with increased binding activity, was evaluated for its potential to replace tacrolimus and protect allogeneic islets in a preclinical primate model. Animals received either the base immunosuppression regimen (rapamycin and anti-IL-2R monoclonal antibody [mAb]) or the base immunosuppression and LEA29Y. Animals receiving the LEA29Y/rapamycin/anti-IL-2R regimen (n = 5) had significantly prolonged islet allograft survival (204, 190, 216, 56, and >220 days). In contrast, those animals receiving the base regimen alone (n = 2) quickly rejected the transplanted islets at 1 week (both at 7 days). The LEA29Y-based regimen prevented the priming of anti-donor T- and B-cell responses, as detected by interferon-gamma enzyme-linked immunospot and allo-antibody production, respectively. The results of this study suggest that LEA29Y is a potent immunosuppressant that can effectively prevent rejection in a steroid-free immunosuppressive protocol and produce marked prolongation of islet allograft survival in a preclinical model.